关于使用0.5%氟尿嘧啶乳膏治疗老年患者光化性角化病的注意事项。
Considerations for use of Fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patients.
作者信息
Werschler William Philip
机构信息
Department of Medicine/Dermatology, University of Washington School of Medicine, Seattle, Washington.
出版信息
J Clin Aesthet Dermatol. 2008 Jul;1(2):22-7.
Actinic keratosis (AK), the initial lesion in a disease continuum that may progress to squamous cell carcinoma, often begins with ultraviolet B light-induced photo damage and increases in prevalence with age. Topical 5-fluorouracil (5-FU) for the treatment of widespread multiple AK lesions has cure rates of more than 90 percent. The associated skin irritation, however, may lead patients to prematurely discontinue treatment. To improve treatment efficacy and tolerability, 5-FU cream 0.5%, a novel Microsponge(®)-based formulation, was developed. In the elderly population, 5-FU cream 0.5% may be preferable because of its convenient (once daily) administration and its lower potential for irritation and systemic absorption, which may impact adherence to therapy and, thus, possibly increase cure rates.
光化性角化病（AK）是一种疾病连续谱中的初始病变，可能会发展为鳞状细胞癌，通常始于紫外线B光引起的光损伤，并随着年龄增长而患病率增加。外用5-氟尿嘧啶（5-FU）治疗广泛多发的AK病变，治愈率超过90%。然而，相关的皮肤刺激可能会导致患者过早停止治疗。为了提高治疗效果和耐受性，研发了一种新型的基于微海绵（®）的0.5% 5-FU乳膏。在老年人群中，0.5% 5-FU乳膏可能更受青睐，因为其给药方便（每日一次），且刺激和全身吸收的可能性较低，这可能会影响治疗依从性，从而可能提高治愈率。
Zotero 插件